trial · primary record
Ruxolitinib
Hodgkin Lymphoma
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 54 |
| Primary completion | 2027-07 |
| Primary endpoint | Maximum Tolerated Dose |
| Registry ID | NCT03681561 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:44:55.418Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03681561
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Ruxolitinib · approval
- Ruxolitinib · compound